Trial · NCT07909564
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Balance performance measured by Brief-BESTest | Baseline, Week 8, Week 12, and Week 24 | Balance performance will be assessed using the Brief Balance Evaluation Systems Test (Brief-BESTest), which evaluates 6 domains of postural control. Each item is scored from 0 to 3, with a total score ranging from 0 to 24. Higher scores indicate better balance performance. |
| Secondary | Cognitive function measured by Montreal Cognitive Assessment | Baseline, Week 8, Week 12, and Week 24 | Cognitive function will be assessed using the Montreal Cognitive Assessment (MoCA). The total score ranges from 0 to 30, with higher scores indicating better cognitive function. |
| Secondary | Attendance rate | During the 8-week intervention period | Attendance will be assessed as the number of completed intervention sessions out of the total planned sessions during the 8-week intervention period. |
| Secondary | Adherence to the intervention | During the 8-week intervention period | Adherence will be defined as attendance at at least 80% of the planned intervention sessions. |
| Secondary | Completion rate | Up to Week 24 | Completion will be assessed as the proportion of participants who complete the intervention program and follow-up assessments. |
| Secondary | Acceptability measured by RFA-AFSPEQ | Week 8 | Acceptability will be assessed using the self-designed Ring Fit Adventure Acceptability, Feasibility, Safety, and Participation Experience Questionnaire (RFA-AFSPEQ). Higher scores indicate greater acceptance of the intervention. |
| Secondary | The 5-item Brief Symptom Rating Scale (BSRS-5) | Baseline, Week 8, Week 12, and Week 24 | It serves as an assessment of psychological distress and mental health status. Each item is evaluated using a 5-point Likert scale ranging from 0 ("not at all") to 4 ("extremely"). |
| Other | Change in heart rate | During the 8-week intervention period | Heart rate will be measured in beats per minute (bpm) before and after each intervention session. For each session, the within-session change will be calculated as the post-session value minus the pre-session value. The reported value is the average of these within-session changes across the 8 weeks interven. Positive values indicate an increase in heart rate after the session. |
| Other | Change in peripheral oxygen saturation | During the 8-week intervention period | Peripheral oxygen saturation will be measured as a percentage (%) before and after each intervention session. The reported value will be the mean change from pre-session to post-session peripheral oxygen saturation during the 8-week intervention period. |
| Other | Change in systolic blood pressure | During the 8-week intervention period | Systolic blood pressure will be measured in mmHg before and after each intervention session. The reported value will be the mean change from pre-session to post-session systolic blood pressure during the 8-week intervention period. |
| Other | Change in diastolic blood pressure | During the 8-week intervention period | Diastolic blood pressure will be measured in mmHg before and after each intervention session. The reported value will be the mean change from pre-session to post-session diastolic blood pressure during the 8-week intervention period. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07909564/registered